Skip to content

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

A Randomized Trial of Early, Upfront Palliative Radiation Therapy Versus Standard of Care for Patients With Highest Risk Asymptomatic or Minimally Symptomatic Bone Metastases

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03523351
Enrollment
78
Registered
2018-05-14
Start date
2018-05-01
Completion date
2024-04-18
Last updated
2025-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Solid Tumors of Metastatic Disease

Keywords

Palliative Radiation, 18-196

Brief summary

The purpose of the study is to compare the outcome of patients who receive standard treatment versus those who receive preventative radiation and then standard treatment.

Interventions

RADIATIONRadiation Therapy

Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.

DRUGSystemic Therapy

Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

In this trial patients will be divided into 2 cohorts. Patients in Cohort 1 will undergo standard of care therapy for bone metastases. Patients in Cohort 2 will undergo upfront RT to ≤5 highest risk bone metastases first followed by standard of care therapy.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed solid tumor malignancy with greater than 5 sites of metastatic disease detected on imaging. * Has high risk bone metastases that are asymptomatic or minimally symptomatic (not requiring opioids). High risks metastases are defined as: 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) and/or disease with posterior element involvement. * ECOG performance status 0 - 2. * Age ≥ 18 years. * Able to provide informed consent. * Patients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactating.

Exclusion criteria

* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances. * Serious medical co-morbidities precluding radiotherapy. * Pregnant or lactating women. * Target lesion(s) is/are complicated bone metastases that include clinical or radiological evidence of spinal cord compression or impending pathological fracture. * Leptomeningeal disease. * Malignant pleural effusion. * Absolute neutrophil count (ANC) \<1.0 K/mcL and platelet count \<50 K/mcL at time of enrollment. * Patients whose entry to the trial will cause unacceptable clinical delays in their planned management.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Skeletal Related Events (SREs)1 yearwhich will be defined as pathological fractures, spinal cord compression, or palliative radiotherapy and orthopedic surgery to bone.

Countries

United States

Participant flow

Participants by arm

ArmCount
Standard of Care
Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT). Systemic Therapy: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
39
Selective Radiation to ≤5 Highest Risk Bone Metastases
Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement. Radiation Therapy: Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
39
Total78

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath1311
Overall StudyLost to Follow-up23
Overall StudyPatient was not treated on study but enrolled due to progressive disease during active treatment02
Overall StudyWithdrawal by Subject40

Baseline characteristics

CharacteristicStandard of CareTotalSelective Radiation to ≤5 Highest Risk Bone Metastases
Age, Continuous58 years58 years58 years
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants8 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
33 Participants68 Participants35 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants2 Participants2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants4 Participants2 Participants
Race (NIH/OMB)
Black or African American
4 Participants10 Participants6 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants4 Participants3 Participants
Race (NIH/OMB)
White
32 Participants60 Participants28 Participants
Region of Enrollment
United States
39 Participants78 Participants39 Participants
Sex: Female, Male
Female
17 Participants35 Participants18 Participants
Sex: Female, Male
Male
22 Participants43 Participants21 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
28 / 3919 / 39
other
Total, other adverse events
34 / 3935 / 39
serious
Total, serious adverse events
4 / 392 / 39

Outcome results

Primary

Number of Participants With Skeletal Related Events (SREs)

which will be defined as pathological fractures, spinal cord compression, or palliative radiotherapy and orthopedic surgery to bone.

Time frame: 1 year

ArmMeasureGroupValue (NUMBER)
Standard of CareNumber of Participants With Skeletal Related Events (SREs)Skeletal Related Events10 number of participants
Standard of CareNumber of Participants With Skeletal Related Events (SREs)No Skeletal Related Events29 number of participants
Selective Radiation to ≤5 Highest Risk Bone MetastasesNumber of Participants With Skeletal Related Events (SREs)Skeletal Related Events1 number of participants
Selective Radiation to ≤5 Highest Risk Bone MetastasesNumber of Participants With Skeletal Related Events (SREs)No Skeletal Related Events38 number of participants

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026